Antiviral Activities of Glycyrrhizin and Its Modified Compounds against Human Immunodeficiency Virus Type 1 (HIV-1) and Herpes Simplex Virus Type 1 (HSV-1) in Vitro

Kazuhiro HIRABAYASHI; Susumu IWATA; Hiroatsu MATSUMOTO; Takeo MORI; Shoji SHIBATA; Masanori BABA; Masahiko ITO; Shiro SHIGETA; Hideki NAKASHIMA; Naoki YAMAMOTO

doi:10.1248/cpb.39.112

Kazuhiro HIRABAYASHI, Susumu IWATA, Hiroatsu MATSUMOTO, Takeo MORI, Shoji SHIBATA, Masanori BABA, Masahiko ITO, Shiro SHIGETA, Hideki NAKASHIMA, Naoki YAMAMOTO

Author information

Kazuhiro HIRABAYASHI
Susumu IWATA
Hiroatsu MATSUMOTO
Takeo MORI
Shoji SHIBATA
Masanori BABA
Masahiko ITO
Shiro SHIGETA
Hideki NAKASHIMA
Naoki YAMAMOTO
Author's Organization：
Research Laboratory, Minophagen Pharmaceutical Co., :Department of Bacteriology, Fukushima Medical College
Research Laboratory, Minophagen Pharmaceutical Co.,
Research Laboratory, Minophagen Pharmaceutical Co.,
Research Laboratory, Minophagen Pharmaceutical Co.,
Shibata Laboratory of Natural Medicinal Materials
Department of Bacteriology, Fukushima Medical College
Department of Bacteriology, Fukushima Medical College
Department of Bacteriology, Fukushima Medical College
Department of Virology and Parasitology, Yamaguchi University School of Medicine
Department of Virology and Parasitology, Yamaguchi University School of Medicine

Keywords: glycyrrhizin analog, HIV-1, HSV-1, antiviral activity

JOURNAL FREE ACCESS

1991 Volume 39 Issue 1 Pages 112-115

DOI https://doi.org/10.1248/cpb.39.112

Details

Abstract

Chemically modified compounds of glycyrrhizin have been synthesized and evaluated for their inhibitory effect on the replication of human immunodeficiency virus type 1 (HIV-1) and herpes simplex virus type 1 (HSV-1). Among them, the 11-deoxo compound having a heteroannular diene structure at the C and D rings proved as active against HIV-1 as glycyrrhizin in MT-4 and MOLT-4 cells. It completely inhibited HIV-1-induced cytopathogenicity in both cell lines at a concentration of 0.16mM. The compound was also effective against HSV-1 with a 50% inhibitory concentration of 0.5μM.

Corresponding author

Register with J-STAGE for free!